Variables | Total | ACPA positive | ACPA negative | P value |
---|---|---|---|---|
Number = 83 | Number = 64 | Number = 19 | ||
Sex (Female%) | 62 | 64 | 58 | 0.62 |
Age at arthroscopy (Mean, SD) | 55.98 ± 12.7 | 55.29 ± 12.8 | 58.23 ± 12.3 | 0.47 |
Disease duration to arthroscopy (Median, IQR 25 to 75) months | 45.50 (10.8–122.1) | 34.56 (8.8–122.0) | 79.0 (15.1–126.8) | 0.27 |
Rheumatoid factor (%) | 78 | 87 | 47 | <0.001* |
Extra-articular disease (%) | 31 | 35 | 20 | 0.28 |
Erosive disease (%) | 74 | 72 | 76 | 0.73 |
CRP mg/dl (Median, IQR 25 to 75) | 2.32 (1.0–5.3) | 2.95 (1.0–5.9) | 1.43 (0.7–3.7) | 0.21 |
ESR mm (Median, IQR 25 to 75) | 32 (16.0– 64.0) | 37 (17.5–70.0) | 26 (14.7–39) | 0.07 |
DAS28 (Median, IQR 25 to 75) | 4.74 (3.6–5.5) | 4.81 (3.7–5.5) | 4.74 (3.2–5.5) | 0.52 |
mHAQ (Median, IQR 25 to 75) | 1.19 (0.5–1.5) | 1.25 (0.6–1.6) | 0.56 (0.2–0.7) | 0.10 |
Number of DMARDs (ever), Mean (SD) | 2.20 (1.1) | 2.20 (1.1) | 1.86 (1.1) | 0.89 |
Methotrexate (%), ever | 88.4 | 88.9 | 88.7 | 0.98 |
Biologic treatment (%, before arthroscopy) ever | 40.6 | 40.0 | 42.0 | 0.85 |